
# Hypertension Treatment Protocol for Primary Care Clinicians

*Target: Physicians, PAs, NPs | 780 words | Clinical reference level*

---

## Evidence-Based Treatment Algorithm

### Stage 1: Initial Assessment & Risk Stratification

**Blood Pressure Classification (2017 ACC/AHA Guidelines):**
- Normal: <120/80 mmHg
- Elevated: SBP 120-129 and DBP <80 mmHg  
- Stage 1 HTN: SBP 130-139 or DBP 80-89 mmHg
- Stage 2 HTN: SBP ≥140 or DBP ≥90 mmHg

**Cardiovascular Risk Assessment:**
Use pooled cohort equations to estimate 10-year ASCVD risk:
- **Low risk** (<10%): Lifestyle modifications first
- **Intermediate risk** (10-20%): Consider medication if lifestyle changes insufficient
- **High risk** (>20%): Immediate pharmacotherapy + lifestyle modifications

### Stage 2: Pharmacotherapy Selection

**First-Line Agents (Equal efficacy for most patients):**

1. **ACE Inhibitors**
   - Lisinopril 10-40mg daily
   - Enalapril 5-40mg BID
   - Monitor: SCr, K+ within 1-2 weeks
   - Contraindications: Pregnancy, angioedema history

2. **ARBs** (ACE-I intolerant)
   - Losartan 50-100mg daily
   - Olmesartan 20-40mg daily
   - Better tolerated than ACE-I (no cough)

3. **Thiazide Diuretics**
   - Hydrochlorothiazide 25-50mg daily
   - Chlorthalidone 25mg daily (preferred for outcomes)
   - Monitor: Electrolytes, glucose, uric acid

4. **Calcium Channel Blockers**
   - Amlodipine 2.5-10mg daily
   - Nifedipine XL 30-90mg daily
   - Monitor: Ankle edema, gingival hyperplasia

### Stage 3: Combination Therapy

**When SBP >20 mmHg or DBP >10 mmHg above goal:**
Start with 2-drug combination (preferably single-pill combination for adherence)

**Preferred Combinations:**
- ACE-I/ARB + thiazide diuretic
- ACE-I/ARB + CCB  
- CCB + thiazide diuretic

**Avoid:** ACE-I + ARB combination

### Stage 4: Resistant Hypertension Management

**Definition:** BP remains above goal despite 3 optimally dosed antihypertensives (including diuretic)

**Evaluation Steps:**
1. Confirm true resistance (home BP monitoring, medication adherence)
2. Screen for secondary causes:
   - Primary aldosteronism (aldosterone:renin ratio)
   - Renal artery stenosis (if indicated)
   - Sleep apnea
   - Drug-induced HTN

**Fourth-line agents:**
- Spironolactone 25-50mg daily (most effective)
- Beta-blockers: Metoprolol, carvedilol
- Alpha-blockers: Doxazosin (avoid as monotherapy)

## Special Populations

### Diabetes Mellitus
- **Goal:** <130/80 mmHg
- **Preferred:** ACE-I or ARB (renal protective)
- **Avoid:** High-dose thiazides (glucose intolerance)

### Chronic Kidney Disease
- **Goal:** <130/80 mmHg
- **Preferred:** ACE-I or ARB (slow progression)
- **Monitor:** SCr increase <30% acceptable
- **Avoid:** K+ >5.5 mEq/L

### Heart Failure with Reduced Ejection Fraction
- **Preferred:** ACE-I/ARB + beta-blocker + diuretic
- **Evidence-based:** Carvedilol, metoprolol succinate
- **Goal:** Maximum tolerated doses

### Elderly (≥65 years)
- **Goal:** <130/80 mmHg if tolerated
- **Start low, go slow:** Avoid excessive BP reduction
- **Monitor:** Orthostatic hypotension, falls risk

## Monitoring & Follow-Up

### Initial Phase (First 3 months)
- **Week 2-4:** Check response, adverse effects
- **Month 2-3:** Assess goal achievement
- **Adjust:** Increase dose or add second agent if needed

### Maintenance Phase
- **Stable patients:** Every 3-6 months
- **Annual labs:** SCr, electrolytes, lipids, HbA1c
- **Home BP monitoring:** Validate office readings

### Quality Metrics
- **Target achievement:** 80% of patients at goal BP
- **Medication adherence:** >80% prescription fill rate
- **Annual ASCVD risk assessment:** All hypertensive patients

## Clinical Decision Points

**When to refer to cardiology/nephrology:**
- Resistant hypertension despite 4 agents
- Secondary hypertension suspected
- Complex comorbidities requiring specialist input
- Rapid progression of kidney disease

**Patient education priorities:**
- DASH diet principles
- Sodium restriction (<2.3g daily)
- Weight management (target BMI <25)
- Regular aerobic exercise (150 min/week)
- Medication adherence strategies

---

*Protocol developed using current ACC/AHA, ESC/ESH guidelines and peer-reviewed evidence. Last updated: 2024.*
